跳至主要内容
临床试验/JPRN-jRCT2080223499
JPRN-jRCT2080223499已完成3 期

Phase III Clinical Study of JTE-052 - Randomized Controlled and Long-term Extension Study in Patients with Atopic Dermatitis

Japan Tobacco Inc.0 个研究点目标入组 158 人开始时间: 2017年3月31日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
158

研究概览

简要总结

ollowing dermal application of JTE-052 ointment 0.5% twice daily for 4 weeks in patients with atopic dermatitis, the percent improvement in mEASI score at the EOT was significantly greater in the JTE-052 ointment 0.5% group than in the placebo group, demonstrating the superiority of the JTE-052 ointment 0.5% group over the placebo group. This study confirmed that dermal application of JTE-052 ointment 0.5% twice daily for 28 weeks was safe and well tolerated in Japanese patients with atopic dermatitis.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 16age old 至 ot applicable(—)
性别
All

入选标准

  • Patients with moderate or severe atopic dermatitis
  • -Modified Eczema Area and Severity Index (mEASI) >=10

排除标准

  • Patients with active infection at the study drug application site
  • Use of topical corticosteroids (strongest or very strong) within 28 days before baseline
  • Use of topical corticosteroids (strong, medium or weak) within 7 days before baseline

研究者

相似试验